Beigene divulges new EGFR mutant-targeting PROTACs for cancer

Nov. 25, 2022

Beigene Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to an EGFR (mutant)-targeting moiety via linker.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Nov. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 14, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...